Items tagged with Drug-resistant TB
Advocacy campaign and petition call for universal access to six-month drug-resistant TB cures (post with simple image)
The Fast Track the Cure campaign demands universal access to six-month drug-resistant TB cure by 2024.
MSF demands J&J give up its patent monopoly on TB drug to put lives over profits (post with simple image)
Access to TB drug bedaquiline, a backbone medicine for drug-resistant TB treatment regimens, remains out of reach for too many.
WHO publishes information notes on the use of bedaquiline and delamanid in children and adolescents with drug-resistant TB (post with simple image)
The information notes complement the updated WHO guidelines and operational handbook on the management of TB in children and adolescents released in 2022.
Urgent action necessary for equitable access to bedaquiline in all countries with high burdens of TB, MDR-TB, and TB/HIV (post with simple image)
Advocates demand that Johnson & Johnson commit to non-enforcement of secondary patent on bedaquiline so that access to generic, quality-assured bedaquiline is guaranteed after the primary patent expires on 18 July 2023.
Global Drug Facility update on access to bedaquiline (post with simple image)
Global Drug Facility announces an agreement with Johnson & Johnson for access to affordable generic versions of bedaquiline; Treatment Action Group, Médecins Sans Frontières and Partners in Health release statements in response to the agreement.
Open letter to Johnson & Johnson requesting clarification on the recent deal on generic bedaquiline supply (post with simple image)
Advocates call for clarity on the terms of the Johnson & Johnson's deal with the Stop TB Partnership’s Global Drug Facility to supply generic bedaquiline.
Global Drug Facility announces price reductions up to 55% for bedaquiline (post with simple image)
The new prices are valid through December 2024 and present price reductions up to 55% compared to the previous price of US$289 for a 6-month treatment course of bedaquiline.
Open letters to Johnson & Johnson requesting equitable access to bedaquiline (post with simple image)
Ukraine, Belarus, Azerbaijan and Moldova demand that Johnson & Johnson take urgent action to improve equitable access to bedaquiline in all countries with a high burden of TB.
Johnson & Johnson confirms intent not to enforce patents for SIRTURO® (bedaquiline) for the treatment of multidrug-resistant TB in 134 low- and middle-income countries (post with simple image)
The decision is intended to assure current and future generic manufacturers that they may manufacture and sell generic versions of SIRTURO® without a concern that the Company will enforce its bedaquiline patents, provided the generic versions of SIRTURO® are of good quality, medically acceptable, and are used only in the 134 low- and middle-income countries.
Johnson & Johnson pricing agreement for critical TB drug still unfairly restricts access in countries where the need is greatest (post with simple image)
Unitaid calls on Johnson & Johnson to drop secondary patents for the drug-resistant TB medicine bedaquiline, and to make negotiated rates with the Stop TB Partnership’s Global Drug Facility available to all countries, regardless of how they purchase drugs.
Page 115 of 117 · Total posts: 0
←First 114 115 116 Last→